While Sarepta’s gene therapy for the treatment of DMD called Elevidys was approved by the FDA in 2023, Regenxbio is developing its treatment.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy